How much does Crizotinib cost for an individual after insurance?

Crizotinib (Crizotinib) is an oral, targeted therapy drug used to treat a specific type of cancer, tyrosine kinase fusion-positive non-small cell lung cancer (NSCLC). The drug was originally developed by Pfizer (Pfizer) and was approved by the U.S. Food and Drug Administration (FDA) in 2011.

Crizotinib is currently on the market in China and is included in medical insurance. Patients can purchase it domestically. The price is around 6,000~12,000 yuan. Since the price of medical insurance policies varies greatly in various places, please consult the local pharmacy or medical insurance bureau for specific prices. There are original and generic versions of crizotinib available abroad. The original version is mainly Pfizer’s original drug, and the price is around 11,000 yuan. Generic drugs are mainly from Bangladesh and Laos. Due to different pharmaceutical manufacturers and drug specifications, generic drugs cost around 2,700~3,000 yuan. Moreover, the ingredients of foreign original drugs and generic drugs are basically the same as those of domestic drugs.

Crizotinib plays a therapeutic role in some NSCLC patients by inhibiting an abnormal tyrosine kinase called ALK protein (Anaplastic Lymphoma Kinase) and the ROS1 fusion protein. Abnormalities in these genes can lead to abnormalities in cell growth and proliferation, leading to the development of cancer.

The drug is used to treat patients with locally advanced or metastatic ALKfusion-positive NSCLC and ROS1fusion-positive NSCLC patients. Typically, doctors test a patient's genotype before determining whether a patient is a candidate for crizotinib.

Although crizotinib is excellent at treating certain types of lung cancer, as a drug, it can also cause some side effects. Common side effects may include nausea, vomiting, diarrhea, fatigue, loss of appetite, etc. Regular monitoring and close follow-up are very important for patients taking crizotinib so that any possible side effects can be detected early and managed.